Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection

Although antibody levels progressively decrease following SARS-CoV-2 infection, the immune memory persists for months. Thus, individuals who naturally contracted SARS-CoV-2 are expected to develop a more rapid and sustained response to COVID-19 vaccines than naïve individuals. In this study, we anal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Viruses Jg. 13; H. 3; S. 422
Hauptverfasser: Gobbi, Federico, Buonfrate, Dora, Moro, Lucia, Rodari, Paola, Piubelli, Chiara, Caldrer, Sara, Riccetti, Silvia, Sinigaglia, Alessandro, Barzon, Luisa
Format: Journal Article
Sprache:Englisch
Veröffentlicht: Switzerland MDPI 05.03.2021
MDPI AG
Schlagworte:
Adult
anti-spike RBD IgG antibody
Antibodies, Viral - immunology
Antibody Formation
BNT162b2 vaccine
Communication
COVID-19 - immunology
COVID-19 - prevention & control
COVID-19 - virology
COVID-19 infection
COVID-19 vaccine
COVID-19 Vaccines - administration & dosage
COVID-19 Vaccines - genetics
COVID-19 Vaccines - immunology
Female
health services
Humans
immune response
Immunoglobulin G - immunology
immunologic memory
Male
Middle Aged
neutralizing antibody
pain
RNA, Messenger - administration & dosage
RNA, Messenger - genetics
RNA, Messenger - immunology
RNA, Viral - administration & dosage
RNA, Viral - genetics
RNA, Viral - immunology
SARS-CoV-2
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
vaccines
anti-spike RBD IgG antibody
BNT162b2 vaccine
SARS-CoV-2
immune response
reactogenicity
COVID-19 vaccine
neutralizing antibody
immunogenicity
vaccine doses
vaccination
ISSN:1999-4915, 1999-4915
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Although antibody levels progressively decrease following SARS-CoV-2 infection, the immune memory persists for months. Thus, individuals who naturally contracted SARS-CoV-2 are expected to develop a more rapid and sustained response to COVID-19 vaccines than naïve individuals. In this study, we analyzed the dynamics of the antibody response to the BNT162b2 mRNA COVID-19 vaccine in six healthcare workers who contracted SARS-CoV-2 in March 2020, in comparison to nine control subjects without a previous infection. The vaccine was well tolerated by both groups, with no significant difference in the frequency of vaccine-associated side effects, with the exception of local pain, which was more common in previously infected subjects. Overall, the titers of neutralizing antibodies were markedly higher in response to the vaccine than after natural infection. In all subjects with pre-existing immunity, a rapid increase in anti-spike receptor-binding domain (RBD) IgG antibodies and neutralizing antibody titers was observed one week after the first dose, which seemed to act as a booster. Notably, in previously infected individuals, neutralizing antibody titers 7 days after the first vaccine dose were not significantly different from those observed in naïve subjects 7 days after the second vaccine dose. These results suggest that, in previously infected people, a single dose of the vaccine might be sufficient to induce an effective response.
Bibliographie:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
These authors contributed equally to this work.
ISSN:1999-4915
1999-4915
DOI:10.3390/v13030422